Dec 20, 2023 7:00 am EST Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 1, 2023 7:00 am EST Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
Nov 14, 2023 7:00 am EST Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
Nov 13, 2023 7:00 am EST Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
Nov 8, 2023 4:30 pm EST Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
Nov 3, 2023 7:00 am EDT Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas
Nov 2, 2023 4:06 pm EDT Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy
Oct 24, 2023 7:00 am EDT Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting
